Antibody matrix device and method for evaluating immune status

• US 5,100,777 A
• Filed: 04/27/1987
• Issued: 03/31/1992
• Est. Priority Date: 04/27/1987
• Status: Expired due to Term

• Current Assignee: Tanox Biosystems Inc. (Roche Holding AG)
• Original Assignee: Tanox Biosystems Inc. (Roche Holding AG)
• Inventors: Chang, Tse W.
• Primary Examiner(s): SAUNDERS, DAVID A
• Application Number:
  US07/043,206
• Time in Patent Office: 1,800 Days
• Field of Search: 436/501, 436/518, 436/519, 436/531, 436/532, 436/527, 436/809, 436/815, 436/510, 436/548, 436/811, 435/7, 435/5, 435/7.24, 422/57, 935/110
• US Class Current: 435/7.24
• CPC Class Codes: G01N 33/54366 Apparatus specially adapted for solid-phase testing
• CPC Class Codes: G01N 33/54386 Analytical elements
• CPC Class Codes: G01N 33/545 Synthetic resin
• CPC Class Codes: G01N 33/552 Glass or silica
• CPC Class Codes: G01N 33/56972 White blood cells
• CPC Class Codes: G01N 33/56988 HIV or HTLV
• CPC Class Codes: Y10S 436/809 Multifield plates or multicontainer arrays
• CPC Class Codes: Y10S 436/811 Test for named disease, body condition or organ function

Abstract

An antibody matrix immunoassay device for determination of number and proportion of subpopulations of leukocytes is described. The device can be used to evaluate and monitor the immune status of an individual and to diagnose and monitor the progression of AIDS.

Claims

1. An immunoassay device comprising:

a. support having a substantially planar surface;

b. an array of small, closely-spaced, discrete, antibody-coated areas on the support surface, the array containing antibody coated areas each area individually containing one of the following antibodies;

a. antibody specific for surface antigen present on all mononuclear leukocytes;

b. antibody specific for surface antigen present on all B lymphocytes;

c. antibody specific for surface antigens present on all T lymphocytes;

d. antibody specific for surface antigen present on helper/inducer T lymphocytes;

e. antibody specific for surface antigen present on suppressor/cytotoxic T lymphocytes; and

f. antibody specific for surface antigen present on monocytes; and

c. a cover spaced from the support surface and positioned over the array of antibody coated areas,

the cover having at least one aperture communicating with the interior of the chamber for introducing a suspension of leukocytes into the chamber, and,

at least one additional aperture in the cover also communicating with the interior of the chamber to allow air to escape upon introduction of the sample into the chamber.

2. An immunoassay device according to claim 1, wherein the antibodies in the antibody-coated areas are selected from the group consisting of:

a. antibody specific for β

₂ microglobulin;

b. antibody specific for immunoglobulin G or M;

c. antibody specific for surface antigen CD3;

d. antibody specific for surface CD4;

e. antibody specific for surface antigen CD8; and

f. antibody specific for OKM1 antigen.

3. An immunoassay device of claim 1, wherein all of the antibody-coated areas are of substantially the same size and shape.

4. An immunoassay device according to claim 1, wherein the support is a glass microscope slide.

5. An immunoassay device according to claim 1, wherein the support is a plastic microscope slide.

6. An immunoassay device according to claim 1, wherein the array of discrete, antibody-coated areas is a rectangular matrix.

7. An immunoassay device of claim 1, wherein the antibody coated areas are formed by applying solutions of antibody to the support surface of from about 10 to about 20 ug/ml.

8. An immunoassay device of claim 1, wherein the cover is detachably secured to the surface of the support.

9. An immunoassay device of claim 1, wherein the cover is substantially rectangular and planar and is mounted upon walls which are secured to the surface of the support and extend upwardly therefrom.

10. An immunoassay device of claim 1, wherein the surface of the planar support is coated with a visible, inert, water repellant, material except where the antibody coated spots are located.

11. An immunoassay device of claim 10, wherein the coating material is tetrafluoroethylene or fluorinated ethylene-propylene.

15. A method of determining the numbers and relative proportions of leukocyte subpopulations in the blood of an individual, comprising:

a. isolating leukocytes from the blood of an individual;

b. introducing a sample of the isolated leukocytes into the chamber of an immunoassay device of claim 11, 12 or 14;

c. allowing the leukocytes to settle onto the surface;

d. removing nonadherent cells; and

e. determining the number and proportion of leukocyte types by determining the number of leukocytes adhered to a type-specific spot.

12. An immunoassay device, comprising:

a. a support having a substantially planar surface;

b. a rectangular array of antibody-coated spots on the planar surface, the array of antibody-coated spots containing a spot or set of spots containing antibodies specific for β

₂ microglobulin, a spot or set of spots containing antibody specific for immunoglobulin G, a spot or set of spots containing antibody specific for CD3 antigen, a spot or set of spots containing antibody specific for CD4 antigen, a spot or set of spots containing antibody specific for CD8 antigen, and a spot or set of spots containing antibody specific for OKM1 antigen;

c. walls extending upwardly from the support surface and located at the perimeter of each array of antibody-coated spots; and

d. a cover mounted upon the walls thereby forming an enclosed chamber over each array, the cover having a sample injection aperture communicating with the chamber space and a plurality of apertures also communicating with the chamber space to permit air to escape.

13. A device of claim 12, wherein the support and chamber are made of glass or plastic.

14. An immunoassay device of claim 12, wherein the array of antibody spots is comprised of three types of spots:

a. antibody specific for surface antigen CD3;

b. antibody specific for surface CD4; and

c. antibody specific for surface antigen CD8.

16. An immunoassay device for monitoring the immune status of an individual infected with HIV, or diagnosed as having AIDS or ARC, comprising:

(i) a support having a substantially planar surface;

(ii) a rectangular array of antibody-coated spots on the planar surface, the array of antibody-coated spots containing antibodies specific for surface antigen present on leukocytes T lymphocytes, helper/inducer T lymphocytes and suppressor/cytotoxic T lymphocytes;

(iii) walls extending upwardly from the support surface and located at the perimeter of each array of antibody-coated spots; and

(iv) a cover mounted upon the walls, thereby forming an enclosed chamber over each array, the cover having a sample injection aperture communicating with the chamber and a plurality of apertures also communicating with the chamber to permit air to escape;

wherein the support, walls and cover are made of glass or plastic.

17. An immunoassay device of claim 16, wherein the antibodies specific for antigens present on T lymphocytes, helper/inducer T lymphocytes and suppressor/cytotoxic T lymphocytes are anti-CD3 antibody, OTK4 antibody and OTK8 antibody, respectively.

18. A method of monitoring the immune status of an individual infected with HIV, or diagnosed as having AIDS or ARC, comprising the steps of:

a. isolating leukocytes from the blood of the individual;

b. introducing a sample of the isolated leukocytes into the enclosed chamber of an immunoassay device of claim 16;

c. allowing the leukocytes to settle onto the planar surface of the chamber;

d. removing nonadherent cells; and

e. determining the number and proportion of leukocyte types by determining the number of leukocytes adhered to a type-specific spot.